AbbVie Inc (ABBV) : Kanawha Capital Management scooped up 3,125 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 25, 2016. The investment management firm now holds a total of 181,322 shares of AbbVie Inc which is valued at $11,060,642.AbbVie Inc makes up approximately 1.89% of Kanawha Capital Management’s portfolio.
AbbVie Inc opened for trading at $60.79 and hit $62 on the upside on Monday, eventually ending the session at $61.44, with a gain of 0.72% or 0.44 points. The heightened volatility saw the trading volume jump to 95,12,008 shares. Company has a market cap of $98,994 M.
Other Hedge Funds, Including , Montrusco Bolton Investments boosted its stake in ABBV in the latest quarter, The investment management firm added 2,135 additional shares and now holds a total of 8,760 shares of AbbVie Inc which is valued at $538,039. AbbVie Inc makes up approx 0.04% of Montrusco Bolton Investments’s portfolio.Horizon Kinetics boosted its stake in ABBV in the latest quarter, The investment management firm added 135 additional shares and now holds a total of 36,154 shares of AbbVie Inc which is valued at $2,151,525. AbbVie Inc makes up approx 0.06% of Horizon Kinetics’s portfolio.Investors Asset Management Of Georgia Inc Ga Adv boosted its stake in ABBV in the latest quarter, The investment management firm added 830 additional shares and now holds a total of 9,010 shares of AbbVie Inc which is valued at $536,185. AbbVie Inc makes up approx 0.44% of Investors Asset Management Of Georgia Inc Ga Adv’s portfolio.Guinness Asset Management Ltd boosted its stake in ABBV in the latest quarter, The investment management firm added 2,800 additional shares and now holds a total of 75,520 shares of AbbVie Inc which is valued at $4,494,195. AbbVie Inc makes up approx 1.33% of Guinness Asset Management Ltd’s portfolio.
On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.